SOMAPACITAN
Manner of administration:Injection
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Continuing treatment
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Change of drug
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements
Restriction
Indication: Short stature and slow growth
Treatment phase: Continuing treatment
Restriction
Indication: Short stature and slow growth
Treatment phase: Change of drug
Restriction
Indication: Short stature and slow growth
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Short stature and slow growth
Treatment phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 6 | Max qty units: 6 | # of repeats: 1 | DPMQ: $4,236.06 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Sogroya | |||||
Manner of administration:Injection
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Initial treatment
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Recommencement of treatment
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Recommencement of treatment as a reclassified patient
Restriction
Indication: Short stature and slow growth
Treatment phase: Initial treatment
Restriction
Indication: Short stature and slow growth
Treatment phase: Recommencement of treatment
Restriction
Indication: Short stature and slow growth
Treatment phase: Recommencement of treatment as a reclassified patient
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 8 | Max qty units: 8 | # of repeats: 1 | DPMQ: $5,631.64 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Sogroya | |||||
Manner of administration:Injection
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Initial treatment
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Recommencement of treatment
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Recommencement of treatment as a reclassified patient
Restriction
Indication: Short stature and slow growth
Treatment phase: Initial treatment
Restriction
Indication: Short stature and slow growth
Treatment phase: Recommencement of treatment
Restriction
Indication: Short stature and slow growth
Treatment phase: Recommencement of treatment as a reclassified patient
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 8 | Max qty units: 8 | # of repeats: 1 | DPMQ: $3,770.84 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Sogroya | |||||
Manner of administration:Injection
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Continuing treatment
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Change of drug
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements
Restriction
Indication: Short stature and slow growth
Treatment phase: Continuing treatment
Restriction
Indication: Short stature and slow growth
Treatment phase: Change of drug
Restriction
Indication: Short stature and slow growth
Treatment phase: Continuing treatment as a reclassified patient
Restriction
Indication: Short stature and slow growth
Treatment phase: Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 6 | Max qty units: 6 | # of repeats: 1 | DPMQ: $2,840.46 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Sogroya | |||||